Form 4: Organogenesis Holdings Inc. COO Patrick Bilbo Reports Stock and Option Grants

Chief Operating Officer Patrick Bilbo reports the acquisition of restricted stock units and stock options in Organogenesis Holdings Inc.

Summary

• Patrick Bilbo, the Chief Operating Officer of Organogenesis Holdings Inc., filed a Form 4 on February 21, 2025.
• The filing reports the grant of restricted stock units (RSUs) and stock options.
• Bilbo acquired 184,136 shares of Class A Common Stock through RSUs, vesting annually over four years starting February 15, 2025.
• He also acquired options to purchase 190,475 shares of Class A Common Stock at an exercise price of $3.53, exercisable annually over four years beginning February 15, 2025.
• Following these transactions, Bilbo directly owns 949,062 shares of Class A Common Stock and options for 190,475 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of equity to the COO is a standard practice and aligns his interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The grant of RSUs and stock options to the COO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the COO.

Future Outlook

The vesting of RSUs and exercisability of stock options are contingent upon continued service, incentivizing the COO's performance over the next four years.

Industry Context

Granting stock options and RSUs to key executives is a common practice in the industry to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in publicly traded companies, particularly in the biotech and healthcare sectors.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize equity-based compensation to incentivize their executives.
• The vesting schedules and exercise prices are generally in line with industry norms, designed to reward long-term value creation.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Organogenesis Holdings Inc., Patrick Bilbo, Form 4, RSU, Stock Options, Beneficial Ownership, ORGO, COO